Statements from the Taormina expert meeting on occult hepatitis B virus infection

Journal of Hepatology

Volumn 49, Issue 4, 2008, Pages 652-657

  Raimondo, Giovanni ^a   Allain, Jean Pierre ^b   Brunetto, Maurizia R ^c   Buendia, Marie Annick ^d   Chen, Ding Shinn ^e   Colombo, Massimo ^f   Craxì, Antonio ^g   Donato, Francesco ^h   Ferrari, Carlo ⁱ   Gaeta, Giovanni B ^j   Gerlich, Wolfram H ^k   Levrero, Massimo ^l   Locarnini, Stephen ^m   Michalak, Thomas ⁿ   Mondelli, Mario U ^o   Pawlotsky, Jean Michel ^p   Pollicino, Teresa ^a   Prati, Daniele ^f,q   Puoti, Massimo ^h   Samuel, Didier ^r   Shouval, Daniel ^s   Smedile, Antonina ^t   Squadrito, Giovanni ^a   Trépo, Christian ^u   Villa, Erica ^v   Will, Hans ^w   Zanetti, Alessandro R ^f   Zoulim, Fabien ^u   more..

^a UNIVERSITY OF MESSINA   (Italy)

^b Cambridge Blood Centre   (United Kingdom)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d INSTITUT PASTEUR   (France)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

^l Laboratory of Gene Expression   (Italy)

^m VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

ⁿ Division of Basic Medical Sciences   (Canada)

^o FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^p INSERM   (France)

^q A MANZONI HOSPITAL   (Italy)

^r HÔPITAL PAUL BROUSSE   (France)

^s HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^t MOLINETTE HOSPITAL   (Italy)

^u UNIVERSITÉ LYON 1   (France)

^v UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^w UNIVERSITY OF HAMBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE;

ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; ITALY; LIVER NEOPLASMS; RISK FACTORS;

EID: 50949118651     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.014     Document Type: Article

References (53)

1. McMahon B.J. Chronic carriers of hepatitis B virus who clear hepatitis B surface antigen: are they really "off the hook?. Hepatology 28 (1998) 265-267
2. Michalak T.I. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 174 (2000) 98-111
3. Raimondo G., Balsano C., Craxì A., Farinati F., Levrero M., Mondelli M., et al. Occult hepatitis B virus infection. Dig Liver Dis 32 (2000) 822-826
4. Brechot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., and Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely occult?. Hepatology 34 (2001) 194-203
5. Conjeevaram H.S., and Lok A.S. Occult hepatitis B virus infection: a hidden menace?. Hepatology 34 (2001) 204-206
6. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction?. J Hepatol 34 (2001) 471-473
7. Torbenson M., and Thomas D.L. Occult hepatitis B. Lancet Infect Dis 2 (2002) 479-486
8. Munoz S.J. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 8 (2002) S82-S87
9. Hu K.Q. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9 (2002) 243-257
10. Blendis L., Lurie Y., and Oren R. Occult HBV infection - both hidden and mysterious. Gastroenterology 125 (2003) 1903-1905
11. Bowden S., Bartholomeusz A., and Locarnini S. Lamivudine resistant occult HBV: implications for public health?. J Hepatol 38 (2003) 526-528
12. Allain J.P. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 86 (2004) 83-91
13. Marrero J.A., and Lok A.S. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?. Gastroenterology 126 (2004) 347-350
14. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127 (2004) S56-S61
15. Chemin I., and Trepo C. Clinical impact of occult HBV infections. J Clin Virol 34 (2005) S15-S21
16. Chen C.J. Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements. J Hepatol 42 (2005) 438-440
17. Raimondo G., Pollicino T., and Squadrito G. What is the clinical impact of occult hepatitis B virus infection?. Lancet 365 (2005) 638-640
18. Gerlich W., Wagner F., Chudy M., Harritshoj L., Lattermann A., Wienzek S., et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 79 (2006) S32-S36
19. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 45 (2006) 127-143
20. Weber B. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 78 (2006) S59-S65
21. Yeo W., and Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006) 209-220
22. Puoti M., Torti C., Bruno R., Filice G., and Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44 (2006) S65-S70
23. Donato F., Gelatti U., Limina R.M., and Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 25 (2006) 3756-3770
24. Comanor L., and Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 91 (2006) 1-12
25. Zanetti A.R., Romano L., Zappa A., and Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. J Clin Virol 36 (2006) S51-S55
26. Raimondo G., Pollicino T., Cacciola I., and Squadrito G. Occult hepatitis B virus infection. J Hepatol 46 (2007) 160-170
27. Lalazar G., Rund D., and Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136 (2007) 699-712
28. Marzano A., Angelucci E., Andreone P., Brunetto M., Bruno R., Burra P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39 (2007) 397-408
29. Gerlich W.H., Glebe D., and Schuttler C.G. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat 14 (2007) 16-21
30. Mulrooney-Cousins P.M., and Michalak T.I. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 13 (2007) 5682-5686
31. Shouval D. What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C?. Liver Transpl 14 (2008) 418-419
32. Hollinger F.B. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48 (2008) 1001-1026
33. Penna A., Artini M., Cavalli A., Levrero M., Bertoletti A., Pilli M., et al. Long-lasting memory T-cell responses following self-limited acute hepatitis B. J Clin Invest 98 (1996) 1185-1194
34. Michalak T.I., Pasquinelli C., Guilhot S., and Chisari F.V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 93 (1994) 230-239
35. Rehermann B., Ferrari C., Pasquinelli C., and Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 10 (1996) 1104-1108
36. Yotsuyanagi H., Yasuda K., Iino S., Moriya K., Shintani Y., Fujie H., et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27 (1998) 1377-1382
37. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M.E., and Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341 (1999) 22-26
38. Chen Y.C., Sheen I.S., Chu C.M., and Liaw Y.F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123 (2002) 1084-1089
39. Huo T.I., Wu J.C., Lee P.C., Chau G.Y., Lui W.Y., Tsay S.H., et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 28 (1998) 231-236
40. Michalak T.I., Mulrooney P.M., and Coffin C.S. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 78 (2004) 1730-1738
41. Mason A.L., Xu L., Guo L., Kuhns M., and Perrillo R.P. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27 (1998) 1736-1742
42. Marusawa H., Uemoto S., Hijikata M., Ueda Y., Tanaka K., Shimotohno K., et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31 (2000) 488-495
43. Pollicino T., Squadrito G., Cerenzia G., Cacciola I., Raffa G., Craxì A., et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126 (2004) 102-110
44. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 42 (2005) 302-308
45. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004) 1750-1758
46. Pollicino T., Raffa G., Costantino L., Lisa A., Campello C., Squadrito G., et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45 (2007) 277-285
47. Vivekanandan P., Kannangai R., Ray S.C., Thomas D.L., and Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 46 (2008) 1227-1236
48. Blum H., Galun E., Liang T.J., von Weizsacker F., and Wands J.R. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 65 (1991) 1836-1842
49. Chaudhuri V., Tayal R., Nayak B., Acharya S.K., and Panda S.K. Occult hepatitis B virus infection in chronic liver disease full-length genome and analysis of mutant surface promoter. Gastroenterology 127 (2004) 1356-1371
50. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P., et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134 (2008) 1470-1481
51. Raimondo G., Navarra G., Mondello S., Costantino L., Colloredo G., Cucinotta E., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 48 (2008) 743-746
52. Cougot D., Neuveut C., and Buendia M.A. HBV induced carcinogenesis. J Clin Virol 34 (2005) S75-S78
53. Shetty K., Hussain M., Nei L., Reddy K.R., and Lok A.S. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 14 (2008) 534-540